menu

Revolutionary Approaches to Improving Outcomes in Unresected LA SCCHN

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Revolutionary Approaches to Improving Outcomes in Unresected LA SCCHN

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Join our international multidisciplinary panel of experts in exploring revolutionary approaches to treating patients with unresectable locally advanced squamous cell carcinoma of the head and neck. The panel will address key aspects of patient management, including new and emerging therapies, the clinical significance of early endpoints used in clinical trials, and future directions in treatment.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Ezra Cohen, MD, FRCPSC, FASCO
    Chief Medical Officer, Oncology
    Tempus Labs
    Professor of Medicine, Division of Hematology/Oncology
    University of California, San Diego Health
    San Diego, CA

    Consulting Fees: Adagene, Astellas, Cidara, Eisai, Eli Lilly, Genmab, Gilboa, iTeos, Merck, MSD, Nectin Tx, Novartis, Nykode, Pangea Therapeutics, PCI Biotech, Replimune, Roche, Soteria, Tempus, Viracta
    Employee of an ineligible company: Tempus Labs
    Ownership Interest: Kinnate Biopharma, Primmune Therapeutics
    Research: NCI

    Faculty:
    Kevin J. Harrington, MBBS, PhD
    Head, Division of Radiotherapy & Imaging
    The Institute of Cancer Research
    London, UK

    Consulting Fees: AstraZeneca, Boehringer Ingelheim, Merck, MSD, Replimune
    Research: AstraZeneca, Boehringer Ingelheim, Replimune

    Deborah J. Wong, MD, PhD
    Associate Clinical Professor of Medicine
    David Geffen School of Medicine
    University of California, Los Angeles
    Los Angeles, California

    Consulting Fees: Merck Sharp & Dohme
    Research: AstraZeneca, Bicara Therapeutics, Bristol Myers Squibb, F-star Therapeutics, Genentech, Gilead, Kura Oncology, Lilly, Merck Sharp & Dohme, Pfizer, Regeneron, Top Alliance

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.  
    • Andrea Mathis has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Assess the therapeutic potential of emerging agents being investigated for the management of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) and discuss their potential impact on current treatment paradigms
    • Analyze and compare the mechanisms of action of agents currently under investigation for the treatment of LA SCCHN with those of currently available treatment options and discuss potential implications for patient care
    • Describe the evidence, rationale, and clinical significance of early endpoints used in ongoing clinical trials in LA SCCHN
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, pathologists, and other healthcare professionals treating patients with head and neck cancers in the United States.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)


    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from EMD Serono, Inc. EMD Serono, Inc., is the healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Join our international multidisciplinary panel of experts in exploring revolutionary approaches to treating patients with unresectable locally advanced squamous cell carcinoma of the head and neck. The panel will address key aspects of patient management, including new and emerging therapies, the clinical significance of early endpoints used in clinical trials, and future directions in treatment.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Ezra Cohen, MD, FRCPSC, FASCO
    Chief Medical Officer, Oncology
    Tempus Labs
    Professor of Medicine, Division of Hematology/Oncology
    University of California, San Diego Health
    San Diego, CA

    Consulting Fees: Adagene, Astellas, Cidara, Eisai, Eli Lilly, Genmab, Gilboa, iTeos, Merck, MSD, Nectin Tx, Novartis, Nykode, Pangea Therapeutics, PCI Biotech, Replimune, Roche, Soteria, Tempus, Viracta
    Employee of an ineligible company: Tempus Labs
    Ownership Interest: Kinnate Biopharma, Primmune Therapeutics
    Research: NCI

    Faculty:
    Kevin J. Harrington, MBBS, PhD
    Head, Division of Radiotherapy & Imaging
    The Institute of Cancer Research
    London, UK

    Consulting Fees: AstraZeneca, Boehringer Ingelheim, Merck, MSD, Replimune
    Research: AstraZeneca, Boehringer Ingelheim, Replimune

    Deborah J. Wong, MD, PhD
    Associate Clinical Professor of Medicine
    David Geffen School of Medicine
    University of California, Los Angeles
    Los Angeles, California

    Consulting Fees: Merck Sharp & Dohme
    Research: AstraZeneca, Bicara Therapeutics, Bristol Myers Squibb, F-star Therapeutics, Genentech, Gilead, Kura Oncology, Lilly, Merck Sharp & Dohme, Pfizer, Regeneron, Top Alliance

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.  
    • Andrea Mathis has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Assess the therapeutic potential of emerging agents being investigated for the management of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) and discuss their potential impact on current treatment paradigms
    • Analyze and compare the mechanisms of action of agents currently under investigation for the treatment of LA SCCHN with those of currently available treatment options and discuss potential implications for patient care
    • Describe the evidence, rationale, and clinical significance of early endpoints used in ongoing clinical trials in LA SCCHN
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, pathologists, and other healthcare professionals treating patients with head and neck cancers in the United States.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)


    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from EMD Serono, Inc. EMD Serono, Inc., is the healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule14 Jul 2024